Form D · Biotechnology

Intrommune Therapeutics, Inc.

New York, NY · CIK 0001736977

Offering snapshot reported Jan 22, 2024 · SEC filing

Reported sold
$3.28M
Offering amount: $3.28M
Investors reported
15
Form D · investor count
Minimum accepted
$20K
Reported outside-investor minimum
First sale
Mar 16, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 22, 2024Initial$3,278,840No comparison15SEC filing
Jan 22, 2024Initial$210,000No comparison7SEC filing
Jul 8, 2021Amendment$68,043No comparisonNot reportedSEC filing
Jun 23, 2021InitialYet to sellNo comparison0SEC filing
Apr 12, 2018Initial$0No comparison0SEC filing

Offering details

Securities
Debt, Option to acquire, Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-503082
The offering is closed and no amount is currently remaining to be sold.
Note convertible into equity upon occurrence of certain events

Source: Form D, filed Jan 22, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Erick Berglund Director
Nelson Michael Director, Executive
Michael Nelson Director, Executive
Hemanshu Pandya Director
William Reisacher Director
Jonathan Rich Director
Anthony Robinson Promoter

Issuer details

Industry: Biotechnology (See others in industry)

Address:
20 W 125 Th St. Unit #1
New York, NY, 10027